Attana’s presentation from Stora Aktiedagen is now available on Attana’s website

On December 1, Attana attended Aktiespararna’s Stora Aktiedag where CEO, Teodor Aastrup, gave a 20 minute long presentation followed by a 10 minute long Q&A.

The presentation was held in Swedish and primarily focused on Attana’s ongoing diagnostic work and plan going forward, both short- and long-term within both of its business units – Life Science and Diagnostics.

The presentation can be accessed on Attana’s website by following this link:

Attana – Stora Aktiedagen 2021

For more information, please contact:

Teodor Aastrup, CEO
teodor.aastrup@attana.com
+46 (0)8 674 57 00

The Board of directors for Attana consider that the information in this press release is not likely to have a significant effect on the share price but is of general interest for the shareholders and hence should be communicated.

About Attana

Attana was founded in 2002 with the vision of in vitro characterization of molecular interactions mimicking in vivo conditions. Since then, Attana has developed proprietary label free biosensors for biochemical, crude, sera, and cell-based assays and the Attana Virus Analytics (AVA) platform, a proprietary in vitro diagnostics (IVD) tool. Attana products and research services are used by Big Pharma, biotech companies and academic institutions within the life sciences. To learn more about our latest services and products, please visit www.attana.com or contact sales@attana.com